---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-002886"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:37:34.783925+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025

## Summary
- Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.
- R&D expense $8.2M in 2024 vs $4.1M in 2023, driven by $4.9M increase in Phase 3 STAR-1 clinical trial costs.
- Topline results from XYNGARI Phase 3 STAR-1 acne trial expected by end of March 2025.
- Entered Clinical Trial Collaboration Agreement with Revance (Crown Laboratories) to study DMT410 with DAXXIFY for hyperhidrosis.
- G&A expense $4.3M in 2024 vs $4.0M in 2023, primarily due to increased audit fees from auditor change.

## SEC filing metadata
- accession: 0001654954-25-002886
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/0001654954-25-002886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-002886
- JSON: https://secwatch.observer/filing/0001654954-25-002886.json
- Plain text: https://secwatch.observer/filing/0001654954-25-002886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.